Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 208

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 208
---
%
  
    General and administrative 
     1,969,828  
     2,433,893  
     (464,065) 
     (19.1)%
  
    Total operating expenses 
     4,723,791  
     5,148,237  
     (424,446) 
     8.2%
  
    Loss from operations 
     (4,723,791) 
     (5,148,237) 
     (424,446) 
     8.2%

    Other income (expense): 

    Gain from settlement of liabilities with vendor 
     -  
     447,335  
     (447,335) 
     (100.0)%
  
    Other expenses 
     -  
     (630,775) 
     630,775  
     100.0%
  
    Change in fair value of derivative liabilities and earnout liabilities 
     -  
     2,900,000  
     (2,900,000) 
     (100.0)%
  
    Stock-based inducement expense 
     (707,300) 
     -  
     (707,300) 
     (100.0)%
  
    Interest income (expense), net 
     13,776  
     (16,977) 
     30,753  
     181.1%
  
    Total other income (expense), net 
     (693,524) 
     2,699,583  
     (3,393,107) 
     (125.7)%

    Net loss 
     (5,417,315) 
     (2,448,654) 
     (2,968,661) 
     121.2%
  
    Deemed dividend on Series A, Series B and C Preferred Stock 
     (24,700,374) 
     -  
     (24,700,374) 
     100.0%
  
    Net loss attributable to common stockholders 
    $(30,117,689) 
    $(2,448,654) 
    $(27,669,035) 
     1,130.0%

Research
and Development Expenses

Research and development expenses were $2,754,000 for the